80211
document
A controlled trial with diclofensine , a new psychoactive drug , in the treatment of depression . Diclofensine inhibits the uptake of serotonin , noradrenaline and dopamine . In a controlled study , out-patients suffering from moderate to severe depression were treated with the objective of assessing the new drug 's therapeutically effective dose range . Maprotiline was used as a reference drug : fourteen patients were assigned to receive diclofensine and thirteen to receive maprotiline in a double-blind design . Depending on tolerance and efficacy , they were treated for periods ranging from 5 to 150 days . Doses were titrated to the optimum . Findings suggest that a 50 mg daily dose of diclofensine would be sufficient for the majority of the patients . The dosage can be safely increased up to 150 mg daily but this offers few therapeutic advantages . While the efficacy index of the two drugs was similar ( approximately 60 % ) , they differed greatly in their profile of side-effects . No signs of abrupt dissipation of the achieved clinical effects were observed during continued treatment , and no withdrawal reactions were observed when the treatment was stopped . The new drug may be more effective in treating patients in whom a psycho-energizing and mood alleviating effect is desired .
80212
Intervention_Pharmacological
diclofensine
80213
Intervention_Pharmacological
Diclofensine
80214
Intervention_Pharmacological
Maprotiline
80215
Intervention_Pharmacological
diclofensine
80216
Intervention_Pharmacological
maprotiline
80217
Intervention_Pharmacological
diclofensine
80218
Outcome_Physical
efficacy index
80219
Outcome_Adverse-effects
profile of side-effects
80220
Outcome_Other
No signs of abrupt dissipation of the achieved clinical effects
80221
Outcome_Physical
no withdrawal reactions
80222
Outcome_Adverse-effects
effective
80223
Participant_Condition
out-patients suffering from moderate to severe depression
80224
Participant_Sample-size
fourteen
80225
Participant_Sample-size
thirteen